Brand Intelligence Graphcompany
Company Overview
About Baxter International
Baxter International Inc. is a Deerfield, Illinois-based global medical technology company — publicly traded on the New York Stock Exchange (NYSE: BAX) as an S&P 500 component — providing hospitals, nursing homes, ambulatory surgery centers, and home healthcare settings with intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, inhaled anesthetics, advanced surgical equipment, and digital health solutions through approximately 38,000 employees worldwide. In fiscal year 2024, Baxter reported $10.636 billion in revenue from continuing operations with a market capitalization of approximately $15 billion. Baxter has undergone significant strategic transformation: divesting its kidney care business (Vantive) to Carlyle Group for $3.8 billion in January 2025 and its biopharma solutions business for $4.25 billion in 2023, sharpening focus on its three core segments — Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. In July 2025, Baxter appointed Andrew Hider as President and CEO (effective September 2025), bringing operational excellence expertise from his tenure as CEO of ATS (where he doubled revenues and tripled the stock price). Founded in 1931, Baxter introduced the first commercially prepared IV solutions and the first commercially-built kidney dialysis system.
Business Model & Competitive Advantage
Baxter's hospital products and medical technology model addresses the critical care and nutritional support requirements of acute care patients whose conditions require sterile pharmaceutical delivery systems: patients in ICUs, surgical recovery, and long-term care settings require IV fluid and medication delivery that cannot tolerate the contamination risk of compounding pharmacy preparations — and Baxter's factory-prepared IV bags, infusion pumps (SIGMA Spectrum), and parenteral nutrition formulations provide the sterility, dosing accuracy, and clinical workflow integration (BCMA barcode scanning compatibility) that hospital pharmacy and nursing protocols require. Baxter's Hillrom-derived digital health platforms (acquired via the 2022 Hillrom acquisition for $12.5B) include the Welch Allyn vital signs monitoring, Voalte clinical communication, and Centrella smart bed technologies that create the connected care infrastructure for hospital efficiency improvement.
Competitive Landscape 2025–2026
In 2025, Baxter competes in the IV solutions, infusion systems, hospital medical products, and clinical technology market with ICU Medical (NASDAQ: ICUI, IV solutions and infusion, $5.6B revenue after Smiths Medical acquisition), B. Braun (private, German medical, €8B revenue), and Becton Dickinson (NYSE: BDX, infusion and drug delivery, $20.2B revenue) for hospital system GPO contracts, IV solution supply agreements, and smart infusion pump technology placements. The Vantive divestiture ($3.8B to Carlyle, January 2025) ends Baxter's 90-year presence in kidney care — an exit that simplifies the company's portfolio to hospital-focused acute care and surgical products. The new CEO (Andrew Hider, September 2025) arrives with a mandate for operational improvement: Baxter's infusion system market share has faced competitive pressure from ICU Medical and BD following manufacturing disruptions. The 2025 strategy focuses on restoring IV solutions supply chain reliability, integrating the remaining digital health platforms, and improving operating margins under Hider's operational leadership.
The Baxter International Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Baxter International's journey
Leadership Team
Meet the leaders behind Baxter International
Andrew Hider
Andrew Hider was appointed president and CEO in July 2025, with responsibilities beginning no later than September 3, 2025. He previously served as CEO of Cambridge, Ontario-based ATS since 2017, where he led the company's adjusted revenues to nearly double over five years and saw stock price more than triple on the Toronto Stock Exchange.
Brent Shafer
Brent Shafer has served as Chairman and Interim CEO since February 2025, following the retirement of José Almeida. He will transition to independent chairman of the Baxter Board after Andrew Hider assumes the CEO role in September 2025.
Heather Knight
Heather Knight has served as Executive Vice President, Chief Operating Officer, and Interim President of Medical Products & Therapies since February 2025, overseeing operations across Baxter's largest business segment.
Joel Grade
Joel Grade serves as Executive Vice President and Chief Financial Officer, leading Baxter's financial strategy, planning, and reporting across global operations.
Charles Patel
Charles Patel has served as Chief Information Officer and Senior Vice President since 2024, driving technology innovation and digital transformation initiatives across Baxter's healthcare solutions.
Tobi Karchmer
Tobi Karchmer has served as Senior Vice President, Chief Medical Officer, and Chief Scientific Officer since 2021, providing medical and scientific leadership for Baxter's product development and clinical strategies.
Key Differentiators
Market Leader
Baxter International is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Baxter International with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Baxter International? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Baxter International Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Baxter International vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →